HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,173,468 | +42.0% | 528,100 | +34.0% | 0.04% | +44.0% |
| Q2 2023 | $14,210,456 | -9.1% | 393,971 | -3.8% | 0.02% | -13.8% |
| Q1 2023 | $15,633,271 | -25.3% | 409,355 | +11.3% | 0.03% | -38.3% |
| Q4 2022 | $20,926,538 | +26.4% | 367,777 | -12.2% | 0.05% | +27.0% |
| Q3 2022 | $16,553,000 | -4.3% | 418,646 | +6.5% | 0.04% | 0.0% |
| Q2 2022 | $17,299,000 | +5.5% | 393,017 | -4.2% | 0.04% | +12.1% |
| Q1 2022 | $16,393,000 | -8.2% | 410,171 | -7.5% | 0.03% | 0.0% |
| Q4 2021 | $17,856,000 | +17.3% | 443,653 | +18.6% | 0.03% | +3.1% |
| Q3 2021 | $15,226,000 | -13.7% | 374,138 | -3.7% | 0.03% | -17.9% |
| Q2 2021 | $17,635,000 | +3.7% | 388,402 | -4.8% | 0.04% | -9.3% |
| Q1 2021 | $17,005,000 | +29.6% | 408,111 | +32.6% | 0.04% | +26.5% |
| Q4 2020 | $13,117,000 | -6.3% | 307,840 | -42.3% | 0.03% | -17.1% |
| Q3 2020 | $14,000,000 | -4.5% | 533,490 | -2.6% | 0.04% | -10.9% |
| Q2 2020 | $14,664,000 | +63.7% | 547,933 | +9.7% | 0.05% | +39.4% |
| Q1 2020 | $8,959,000 | +443.0% | 499,466 | +435.2% | 0.03% | +560.0% |
| Q4 2019 | $1,650,000 | -27.5% | 93,330 | -36.4% | 0.01% | -16.7% |
| Q3 2019 | $2,277,000 | +0.9% | 146,791 | +11.8% | 0.01% | -14.3% |
| Q2 2019 | $2,257,000 | -8.7% | 131,350 | -14.5% | 0.01% | -12.5% |
| Q1 2019 | $2,473,000 | -63.8% | 153,595 | -59.2% | 0.01% | -66.7% |
| Q4 2018 | $6,838,000 | 0.0% | 376,339 | 0.0% | 0.02% | -4.0% |
| Q3 2018 | $6,838,000 | +20.8% | 376,339 | +12.1% | 0.02% | +31.6% |
| Q2 2018 | $5,662,000 | -10.8% | 335,624 | +3.6% | 0.02% | -20.8% |
| Q1 2018 | $6,348,000 | +1.4% | 324,044 | +4.8% | 0.02% | +9.1% |
| Q4 2017 | $6,261,000 | +11.8% | 309,057 | -4.1% | 0.02% | +10.0% |
| Q3 2017 | $5,598,000 | +30.3% | 322,262 | -3.8% | 0.02% | +17.6% |
| Q2 2017 | $4,295,000 | +7.0% | 335,025 | +8.2% | 0.02% | -5.6% |
| Q1 2017 | $4,014,000 | +32.3% | 309,725 | +0.8% | 0.02% | +20.0% |
| Q4 2016 | $3,034,000 | -3.0% | 307,120 | +18.6% | 0.02% | -6.2% |
| Q3 2016 | $3,127,000 | +62.3% | 258,885 | +15.9% | 0.02% | +33.3% |
| Q2 2016 | $1,927,000 | -7.0% | 223,280 | +2.1% | 0.01% | -7.7% |
| Q1 2016 | $2,072,000 | -44.0% | 218,765 | +2.5% | 0.01% | -43.5% |
| Q4 2015 | $3,697,000 | +15.5% | 213,345 | -10.5% | 0.02% | -20.7% |
| Q3 2015 | $3,202,000 | +35.4% | 238,391 | +127.7% | 0.03% | +38.1% |
| Q2 2015 | $2,364,000 | +161.8% | 104,673 | +65.6% | 0.02% | +162.5% |
| Q1 2015 | $903,000 | – | 63,213 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |